PHARMASUM THERAPEUTICS

pharmasum-therapeutics-logo

Pharmasum Therapeutics AS is a private Norwegian specialty pharmaceutical company focused on the discovery and development of differentiated drugs for the treatment of autoimmune / metabolic and neurological diseases. Founded in 2014 on the spin-out of industrial research on protein kinases, Pharmasum has offices in Tromsรธ and Oslo in Norway, and representation in the UK and USA. The company has an experienced management, board and international team of advisors.

#People #Website #More

PHARMASUM THERAPEUTICS

Industry:
Pharmaceutical

Founded:
2014-01-01

Address:
Tromsรธ, Troms, Norway

Country:
Norway

Website Url:
http://www.pharmasum.com

Total Employee:
1+

Status:
Active

Contact:
+47 92 48 14 32

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Font Awesome Euro ReCAPTCHA Cloudflare JS CDN JS AJAX Libraries API ReCAPTCHA V2


Current Employees Featured

anders-fugelli_image

Anders Fugelli
Anders Fugelli Co-Founder & Chief Executive Officer @ Pharmasum Therapeutics
Co-Founder & Chief Executive Officer

henning-mork_image

Henning Mork
Henning Mork CFO @ Pharmasum Therapeutics
CFO
2014-10-01

Founder


anders-fugelli_image

Anders Fugelli

Official Site Inspections

http://www.pharmasum.com

  • Host name: 104.18.23.21
  • IP address: 104.18.23.21
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Pharmasum Therapeutics"

Pharmasum Therapeutics - Home

Sept 27 โ€“ 29, 2022 Pharmasum Therapeutics presented at Nordic Life Science Days (NLSD) READ MORE >> Jul 19, 2022 Pharmasum Therapeutics announces the publication of an โ€ฆSee details»

Pharmasum Therapeutics - Crunchbase Company Profile & Funding

Pharmasum Therapeutics AS is a private Norwegian specialty pharmaceutical company focused on the discovery and development of differentiated drugs for the treatment of autoimmune / โ€ฆSee details»

Pharmasum Therapeutics โ€“ Invester med hjertet for hjernen

Pharmasum Therapeutics is developing a drug representing a unique innovation in a global market, serving an extremely high unmet medical need. The Most Common Disease of Our โ€ฆSee details»

Pharmasum Therapeutics - Investors

Anders Fugelli. CEO Pharmasum Therapeutics. Phone: +47 924 81 432. Email: [email protected]See details»

Pharmasum Therapeutics AS: Drug pipelines, Patents, Clinical trials ...

Jul 15, 2023 Explore Pharmasum Therapeutics AS with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Nervous โ€ฆSee details»

Pharmasum Therapeutics - Pharmaceutical Companies Database

Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused on the discovery and development of novel drugs for treatment of neurological and โ€ฆSee details»

Pharmasum Therapeutics - Contacts, Employees, Board Members, โ€ฆ

A pharmaceutical company developing drugs for autoimmune/metabolic and neurological diseasesSee details»

Pharmasum Therapeutics - Norway Health Tech

A pharmaceutical company developing drugs for neurological and autoimmune/metabolic diseases. Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused โ€ฆSee details»

Pharmasum Therapeutics AS - 913 746 430 - Oslo - Proff

Pharmasum Therapeutics AS. Org nr 913 746 430. Telefon 924 81 432. Adresse Gaustadalléen 21, 0349 Oslo. Sammenlign Overvåk Finn lignende. Del profil. Oversikt Regnskap Nøkkeltall โ€ฆSee details»

Pharmasum Therapeutics AS - The Hub

Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, โ€ฆSee details»

T&C โ€“ Pharmasum Therapeutics

Pharmasum Therapeutics AS is not responsible or liable for any omissions, errors or inaccuracies in any data or information posted or contained on this site, including but not limited to, product โ€ฆSee details»

pharmasum.com - Pharmasum Therapeutics - Home - Pharmasum โ€ฆ

Pharmasum.com most likely does not offer any adult content. Popular pages. Pharmasum Therapeutics - Home. Nov 17, 2021 Pharmasum Therapeutics announces the publication of โ€ฆSee details»

Pharmasum Therapeutics - The Science behind Pharmasum

Technology | The Science behind Pharmasum Biological processes at the level of enzymes, receptors, ion channels, etc. are regulated via protein phosphorylation catalysed by protein โ€ฆSee details»

Technology โ€“ Scientific Approach โ€“ Pharmasum Therapeutics

Pharmasum Therapeutics has developed PST-674 by using advanced drug design technologies. In collaboration with The Arctic University in Tromsø (UiT), extensive X-ray crystallographic โ€ฆSee details»

PST-1000 - Drug Targets, Indications, Patents - Synapse - Patsnap

Last update 01 Nov 2024. PST-1000. Last update 01 Nov 2024See details»

Pharmasum Therapeutics in Norway - ICH GCP

Pharmasum Therapeutics is a private Norwegian pharmaceutical company focused on the discovery and development of novel drugs for treatment of neurological and โ€ฆSee details»

The Most Common Disease Of Our Time โ€“ Pharmasum Therapeutics

The total estimated worldwide cost of dementia is enormous โ€“ over 1.3 trillion USD (Alzheimerโ€™s Disease International). More than 1% of the annual global value creation is spent on nursing โ€ฆSee details»

Patients โ€“ Clinical Approach โ€“ Pharmasum Therapeutics

The PoC study will be a Phase 1b/2a study in individuals with Down syndrome and dementia. Since there is a close link between DYRK1A and dementia in Down syndrome, this is an ideal โ€ฆSee details»

Pharmasum Therapeutics - T&C

Pharmasum Therapeutics AS is not responsible or liable for any omissions, errors or inaccuracies in any data or information posted or contained on this site, including but not limited to, product โ€ฆSee details»

Pharmasum Therapeutics - Diabetes

Diabetes is a serious condition which can carry a significant risk of both short-term and long-term complications. Growing epidemic with staggering costsSee details»